Pharmaceuticals Global News & Press Release Distribution

Pharmaceuticals

All
APAC

First Patient Dosed in Phase III Perioperative Study of Cadonilimab (PD-1/CTLA-4) in Colon Cancer

HONG KONG, Oct. 10, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the first patient has been dosed in a Phase III clinical study (COMPASSION-40/AK104-313) evaluating cadonilimab, its first-in-class PD-1/CTLA-4 bispecific antibody, as monotherapy in the neoa...

2026-10-10 12:41 3323

Innovent Announces Phase 3 RESTORE-3 Study of SYCUME® (Teprotumumab N01 Injection) Met Primary Endpoint in Inactive Thyroid Eye Disease

* SYCUME® Significantly Improved Proptosis (Response Rate 60.4% / LS Mean Change from Baseline -1.88 mm) with Favorable Safety Profile in Participants with Inactive Thyroid Eye Disease(TED) SAN FRANCISCO and SUZHOU, China, Oct. 8, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX...

2026-10-09 08:00 4089

China SXT Pharmaceuticals Inc. Announces $12 Million Registered Direct Offering

TAIZHOU, China, Oct. 8, 2026 /PRNewswire/ -- China SXT Pharmaceuticals Inc. (NASDAQ: SXTC) (the "Company"), today announced that it has entered into a definitive agreement with certain institutional investors for the purchase and sale of an aggregate of 8,000,000 Class A ordinary shares of the co...

2026-10-08 21:22 6868

SECuRE update: recruitment target of the Cohort Expansion Main Group achieved

SYDNEY, Oct. 8, 2026 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce that the recruitment t...

2026-10-08 21:01 2896

Nuevocor Doses First Patient in SUNBEAM-LMNA Phase 1/2 Trial and Receives FDA Fast Track Designation for NVC-001 in LMNA Dilated Cardiomyopathy

NVC-001 is designed to target the mechanobiological root cause of LMNA dilated cardiomyopathy and has disease-modifying potential SINGAPORE, PARIS and PHILADELPHIA, Oct. 8, 2026 /PRNewswire/ -- Nuevocor, a clinical-stage biotechnology company pioneering mechanobiology-targeted therapies designed...

2026-10-08 19:30 6219

WuXi AppTec Earns EcoVadis Gold Medal for Third Consecutive Year, Ranking Among Global Top 5% for Sustainability

SHANGHAI, Oct. 7, 2026 /PRNewswire/ -- WuXi AppTec, a leading global pharmaceutical CRDMO (Contract Research, Development, and Manufacturing Organization), has received a Gold medal from EcoVadis for the third consecutive year, reflecting the Company's consistent commitment to sustainability. E...

2026-10-08 08:00 3469

Asieris Pharmaceuticals Enters an Exclusive Licensing Agreement with Theramex for CEVIRA® subject to certain conditions, Advancing the Global Development and Commercialization of a Non-Surgical Treatment for Cervical Precancerous Lesions in Europe

* Agreement is expected to grant Theramex exclusive rights to CEVIRA® in Europe, Australia, New Zealand and Turkey, while Asieris retains rights for the rest of the world. * The deal includes 15 million US dollars of upfront payment and a total of 11 million dollars of near-term regulatory mi...

2026-10-07 21:35 2948

LG CNS Showcases Pharma-Specific Manufacturing AX at World's Largest Pharma-Biotech Show

* Participates in CPHI Milan 2026, Expanding Manufacturing AX Reach in Pharma * Showcasing key solutions for factory design, production operations, and quality management using the theme "Autonomous Factory in Pharma" SEOUL, South Korea and MILAN, Oct. 7, 2026 /PRNewswire/ -- LG CNS, a leading...

2026-10-07 20:00 2247

LG CNS Showcases Pharma-Specific Manufacturing AX at World's Largest Pharma-Biotech Show

XtalPi Debuts Kodexia™, the World's First Closed-Loop siRNA Platform Combining Generative AI with First-Principles Modeling

* This unified platform integrates sequence design, chemical modification, experimental validation, extrahepatic delivery design, and intellectual property strategy into an integrated computational–experimental workflow, pioneering in vivo efficacy prediction models to accelerate drug developme...

2026-10-06 22:42 5367

Hisun Pharmaceutical Celebrates 70th Anniversary with Global Partners at Milan-Taizhou Night

MILAN, Oct. 6, 2026 /PRNewswire/ -- Zhejiang Hisun Pharmaceutical Co., Ltd. hosted its 70th Anniversary Global Partners Appreciation Dinner in Milan on October 5, the eve of CPHI Milan 2026. Themed "Bridging Cultures, Advancing Health Together," the event brought together leading pharmaceutical c...

2026-10-06 21:32 2233

Hisun Pharmaceutical Celebrates 70th Anniversary with Global Partners at Milan-Taizhou Night

/C O R R E C T I O N -- Piramal Pharma Solutions/

In the news release, Piramal Pharma Solutions Launches New Microbiology Laboratory at Its Lexington, KY Sterile Injectable Facility, issued 06-Oct-2026 by Piramal Pharma Solutions over PR Newswire, we are advised by the company that changes have been made to the caption accompanying the first ima...

2026-10-06 16:59 3317

/C O R R E C T I O N -- Piramal Pharma Solutions/

Dr. Oregonin Completes U.S. FDA Registration for OLTIS DENTAL-X, Unveiling Oral-Care Innovation Rooted in Trans-Pacific Alder Research

Botanical oral-care product bridges 1974 Oregon State University discovery of 'oregonin' with 27 years of natural-product research by South Korean scientists. SEOUL, South Korea, Oct. 6, 2026 /PRNewswire/ -- Dr. Oregonin Inc. today announced that it has completed U.S. Food and Drug Administration...

2026-10-06 13:50 2579

Dr. Oregonin Completes U.S. FDA Registration for OLTIS DENTAL-X, Unveiling Oral-Care Innovation Rooted in Trans-Pacific Alder Research

OMLYCLO® (omalizumab-igec), the first and only FDA-approved interchangeable biosimilar to XOLAIR®, now commercially available in the U.S.

* OMLYCLO® (omalizumab-igec) is the first and onlyFDA-approved omalizumab biosimilar approved for all four indications of XOLAIR® (omalizumab) and designated as interchangeable with XOLAIR; OMLYCLO® will be available in 75 mg/0.5 mL, 150 mg/mL and 300mg/2mL in a single-dose prefilled syringe fo...

2026-10-05 20:45 3795

Energenesis Biomedical and Yoo Young Pharm Sign MOU for ENERGI-F703DFU Development and Commercialization in Korea

TAIPEI, Oct. 5, 2026 /PRNewswire/ -- Energenesis Biomedical Co., Ltd. (TWSE: 6657) today announced that it has signed a Memorandum of Understanding ("MOU") with Yoo Young Pharm. Co., Ltd. ("YYP"), a South Korea-based pharmaceutical company, to explore a collaboration for the development, registra...

2026-10-05 18:00 2732

Symphony™ Randomized Controlled Trial Demonstrates Significantly Improved Healing of Diabetic Foot Ulcers

Published multicenter study found higher complete wound closure rates and faster healing with Symphony plus standard of care AUCKLAND, New Zealand, Oct. 5, 2026 /PRNewswire/ -- Aroa Biosurgery Limited (ASX: ARX), a soft tissue regeneration company, today announced positive results from a prospec...

2026-10-05 12:46 2743

Celaid Therapeutics Completes Second Close of Series B Financing Round

Shionogi & Co., Ltd. and Teikoku Ventures, Inc. Join the Round to Accelerate U.S. Clinical Trial Preparations for CLD-001 TOKYO, Oct. 4, 2026 /PRNewswire/ -- Celaid Therapeutics Inc. (Head Office: Bunkyo-ku, Tokyo, Japan; President and CEO: Nobuyuki Arakawa; "Celaid") today announced the complet...

2026-10-05 09:30 2256

Ractigen Therapeutics Presents Positive First-in-Human Data for RAG-18 at WMS 2026, Establishing Clinical Proof-of-Mechanism for RNA Activation in Duchenne Muscular Dystrophy

* First clinical evidence demonstrating that a systemically delivered small activating RNA (saRNA) can safely upregulate an endogenous target protein in human skeletal muscle in a monogenic disease. * Paired muscle biopsies reveal 3.5- to 5.3-fold increases in sarcolemmal utrophin expression,...

2026-10-03 19:30 6862

/DISREGARD RELEASE: Jiangsu Vcare/

We are advised by Jiangsu Vcare that journalists and other readers should disregard the news release, Jiangsu Vcare Files NDA for Vicagrel Capsules with US FDA, issued 04-Jan-2024 over PR Newswire. ...

2026-10-02 19:12 5097

Abogen Announces Licensing and Option Agreement with Novartis to Advance mRNA-Encoded T-Cell Engager and other potential RNA programs

Includes worldwide license to ABO2203, Abogen's mRNA-encoded CD19xCD3 T-Cell Engager Agreement also gives Novartis exclusive options to license other potential programs leveraging Abogen's RNA proprietary platform SUZHOU, China, Oct. 2, 2026 /PRNewswire/ -- Abogen Biosciences ("Abogen" or the ...

2026-10-02 12:42 3473

Bambusa Therapeutics Initiates Subcutaneous Dosing of BBT001 in Atopic Dermatitis, Following Compelling Intravenous Proof-of-Concept Data

First patient dosed as Bambusa expands global development of its long-acting bispecific antibody targeting both IL-4Rα and IL-31 High-concentration subcutaneous formulation designed to combine BBT001's emerging profile of rapid, deep and durable clinical activity with convenient administration a...

2026-10-01 21:00 3200

1 234 5 6 ... 166